Paid Clinical Trials in Grosse Pointe Woods, MI
As of July 2026, 39 paid clinical trials are recruiting in Grosse Pointe Woods, Michigan. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Grosse Pointe Woods offers studies at sites including Henry Ford Saint John Hospital - Van Elslander for conditions such as Anatomic Stage II Breast Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Grosse Pointe Woods
Trials by drug in Grosse Pointe Woods
Filter results
39 clinical trials
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Family Communications After Genetic Testing
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Mobile Health for Adherence in Breast Cancer Patients
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Top Research Study Locations in Grosse Pointe Woods
Researchers run research studies in Grosse Pointe Woods, MI at 8 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Henry Ford Saint John Hospital - Van Elslander | Anatomic Stage II Breast Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | 32 |
| Henry Ford Saint John Hospital - Academic | Stage IIIB Lung Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | 31 |
| Henry Ford Saint John Hospital - Breast | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8 | 26 |
| Great Lakes Cancer Management Specialists-Van Elslander Cancer Center | Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Elevated CA15-3 or CEA or CA27-29 | 3 |
| Academic Hematology Oncology Specialists | Anatomic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29, Estrogen Receptor Positive | 2 |
| Henry Ford St. John Hospital | COVID-19 SARS-CoV-2 Infection, Multiple Myeloma | 2 |
| Henry Ford St John TM Center for Infectious Disease Research | Coronavirus Disease (COVID-19) | 1 |
| St. John Hospital | Breast Cancer | 1 |
Active & Upcoming Studies in Grosse Pointe Woods (2026)
Recruiting trials in Grosse Pointe Woods grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (31 active studies)
- Family Communications After Genetic Testing · Alliance for Clinical Trials in Oncology
- Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays · Alliance for Clinical Trials in Oncology
Vaccines (2 active studies)
- A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease · Phase 3 · Pfizer
- A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) · Phase 3 · Merck Sharp & Dohme LLC
Common conditions studied in Grosse Pointe Woods
- Anatomic Stage II Breast Cancer AJCC v8 (3 active studies)
- Stage IIIB Lung Cancer AJCC v8 (3 active studies)
- Anatomic Stage IIIA Breast Cancer AJCC v8 (2 active studies)
- Anatomic Stage IIIB Breast Cancer AJCC v8 (2 active studies)
- Anatomic Stage IV Breast Cancer AJCC v8 (2 active studies)
- Breast Cancer (2 active studies)
Leading research sponsors in Grosse Pointe Woods
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
- Alliance for Clinical Trials in Oncology
- ECOG-ACRIN Cancer Research Group
- NRG Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Grosse Pointe Woods?
There are approximately 39 recruiting clinical trials in Grosse Pointe Woods, Michigan listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Grosse Pointe Woods pay participants?
Most recruiting trials in Grosse Pointe Woods compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Grosse Pointe Woods?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Grosse Pointe Woods?
The most common conditions under active study in Grosse Pointe Woods include Anatomic Stage II Breast Cancer AJCC v8 (3), Stage IIIB Lung Cancer AJCC v8 (3), Anatomic Stage IIIA Breast Cancer AJCC v8 (2), Anatomic Stage IIIB Breast Cancer AJCC v8 (2), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Grosse Pointe Woods?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Grosse Pointe Woods on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Grosse Pointe Woods?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Grosse Pointe Woods?
Recruiting research sites in Grosse Pointe Woods include Henry Ford Saint John Hospital - Van Elslander, Henry Ford Saint John Hospital - Academic, Henry Ford Saint John Hospital - Breast, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Grosse Pointe Woods right now?
The largest active categories in Grosse Pointe Woods are Cancer & tumors (31), Vaccines (2). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.